MP28-13 PROGNOSTIC UTILITY OF BIOPSY-DERIVED CELL CYCLE PROGRESSION SCORE IN PATIENTS WITH NCCN LOW-RISK PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE | Zendy

AI Assistant Blog Pricing

MP28-13 PROGNOSTIC UTILITY OF BIOPSY-DERIVED CELL CYCLE PROGRESSION SCORE IN PATIENTS WITH NCCN LOW-RISK PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.